|
|
Article: Cytokine PharmaSciences, Inc. Issued Patent for MIF Gene Polymorphism Diagnostics.
- Article from:
- PR Newswire
- Article date:
- May 3, 2007
CopyrightCOPYRIGHT 2007 PR Newswire Association LLC. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
KING OF PRUSSIA, Pa., May 3 /PRNewswire/ -- Cytokine PharmaSciences, Inc. (CPSI) today announced issuance of US Patent 7,205,107 entitled "Macrophage migration inhibitory factor (MIF) promoter polymorphism in inflammatory disease." This patent, together with US Patent 6,998,238 issued in 2006 and entitled "Method for determining MIF content," expands the Company's MIF intellectual property portfolio to include MIF diagnostics.
CPSI has an extensive patent portfolio focused on MIF, including methods for neutralization. Excess production of MIF is linked to many conditions, including arthritis, asthma, cancer, sepsis, inflammatory bowel disease and various ...